Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 May;65(5):1606–1614. doi: 10.1128/iai.65.5.1606-1614.1997

Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria.

I S Soares 1, G Levitus 1, J M Souza 1, H A Del Portillo 1, M M Rodrigues 1
PMCID: PMC175182  PMID: 9125537

Abstract

In this study, we evaluated the naturally acquired immune response to Plasmodium vivax merozoite surface protein 1 (PvMSP1) in individuals with recent clinical episodes of malaria from the state of Para, Brazil. Ten recombinant proteins representing the first 682 amino acids (aa) of the N-terminal region and one representing the final 111 aa of the C-terminal region were expressed in Escherichia coli as glutathione S-transferase fusion proteins. Both of these regions have been suggested as candidates for development of a vaccine against Plasmodium sp. The total frequencies of individuals with antibodies and cellular immune responses to PvMSP1 were high (83.8 and 75%, respectively). The recombinant proteins representing the N- and C-terminal regions were recognized by 51.4 and 64.1% of sera, respectively. The frequency of responders to the C-terminal region increased according to the number of previous malaria episodes, reaching 83.3% after four episodes. Cellular immune response was measured by in vitro proliferation and gamma interferon production. Peripheral blood mononuclear cells of 75 and 47.2% of individuals proliferated in response to stimulation by the N- and C-terminal regions, respectively. Also, we found that one protein representing the N terminus and a second representing the C terminus of PvMSP1 stimulated 54.5% of individuals to secrete gamma interferon. We concluded that PvMSP1 is immunogenic to a large proportion of individuals exposed to malaria. Our results also suggested that the C-terminal region of PvMSP1 containing the two epidermal growth factor-like domains is particularly immunogenic to antibodies and T cells during natural infection in humans.

Full Text

The Full Text of this article is available as a PDF (423.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams J. H., Sim B. K., Dolan S. A., Fang X., Kaslow D. C., Miller L. H. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7085–7089. doi: 10.1073/pnas.89.15.7085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barnwell J. W., Galinski M. R. Plasmodium vivax: a glimpse into the unique and shared biology of the merozoite. Ann Trop Med Parasitol. 1995 Apr;89(2):113–120. doi: 10.1080/00034983.1995.11812941. [DOI] [PubMed] [Google Scholar]
  3. Blackman M. J., Heidrich H. G., Donachie S., McBride J. S., Holder A. A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med. 1990 Jul 1;172(1):379–382. doi: 10.1084/jem.172.1.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blackman M. J., Ling I. T., Nicholls S. C., Holder A. A. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol. 1991 Nov;49(1):29–33. doi: 10.1016/0166-6851(91)90127-r. [DOI] [PubMed] [Google Scholar]
  5. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990 Dec 1;172(6):1633–1641. doi: 10.1084/jem.172.6.1633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  7. Burns J. M., Jr, Parke L. A., Daly T. M., Cavacini L. A., Weidanz W. P., Long C. A. A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii. J Immunol. 1989 Apr 15;142(8):2835–2840. [PubMed] [Google Scholar]
  8. Chang S. P., Case S. E., Gosnell W. L., Hashimoto A., Kramer K. J., Tam L. Q., Hashiro C. Q., Nikaido C. M., Gibson H. L., Lee-Ng C. T. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun. 1996 Jan;64(1):253–261. doi: 10.1128/iai.64.1.253-261.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chang S. P., Gibson H. L., Lee-Ng C. T., Barr P. J., Hui G. S. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol. 1992 Jul 15;149(2):548–555. [PubMed] [Google Scholar]
  10. Chappel J. A., Holder A. A. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol. 1993 Aug;60(2):303–311. doi: 10.1016/0166-6851(93)90141-j. [DOI] [PubMed] [Google Scholar]
  11. Cheng Q., Stowers A., Huang T. Y., Bustos D., Huang Y. M., Rzepczyk C., Saul A. Polymorphism in Plasmodium vivax MSA1 gene--the result of intragenic recombinations? Parasitology. 1993 May;106(Pt 4):335–345. doi: 10.1017/s003118200006707x. [DOI] [PubMed] [Google Scholar]
  12. Daly T. M., Long C. A. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun. 1993 Jun;61(6):2462–2467. doi: 10.1128/iai.61.6.2462-2467.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Daly T. M., Long C. A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol. 1995 Jul 1;155(1):236–243. [PubMed] [Google Scholar]
  14. Egan A. F., Chappel J. A., Burghaus P. A., Morris J. S., McBride J. S., Holder A. A., Kaslow D. C., Riley E. M. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun. 1995 Feb;63(2):456–466. doi: 10.1128/iai.63.2.456-466.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Egan A. F., Morris J., Barnish G., Allen S., Greenwood B. M., Kaslow D. C., Holder A. A., Riley E. M. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis. 1996 Mar;173(3):765–769. doi: 10.1093/infdis/173.3.765. [DOI] [PubMed] [Google Scholar]
  16. Fern J., Good M. F. Promiscuous malaria peptide epitope stimulates CD45Ra T cells from peripheral blood of nonexposed donors. J Immunol. 1992 Feb 1;148(3):907–913. [PubMed] [Google Scholar]
  17. Galinski M. R., Medina C. C., Ingravallo P., Barnwell J. W. A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell. 1992 Jun 26;69(7):1213–1226. doi: 10.1016/0092-8674(92)90642-p. [DOI] [PubMed] [Google Scholar]
  18. Gibson H. L., Tucker J. E., Kaslow D. C., Krettli A. U., Collins W. E., Kiefer M. C., Bathurst I. C., Barr P. J. Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax. Mol Biochem Parasitol. 1992 Feb;50(2):325–333. doi: 10.1016/0166-6851(92)90230-h. [DOI] [PubMed] [Google Scholar]
  19. Holder A. A., Freeman R. R. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature. 1981 Nov 26;294(5839):361–364. doi: 10.1038/294361a0. [DOI] [PubMed] [Google Scholar]
  20. Holder A. A., Riley E. M. Human immune response to MSP-1. Parasitol Today. 1996 May;12(5):173–206. doi: 10.1016/0169-4758(96)20009-2. [DOI] [PubMed] [Google Scholar]
  21. Holder A. A. The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy. 1988;41:72–97. [PubMed] [Google Scholar]
  22. Kumar S., Yadava A., Keister D. B., Tian J. H., Ohl M., Perdue-Greenfield K. A., Miller L. H., Kaslow D. C. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med. 1995 Mar;1(3):325–332. [PMC free article] [PubMed] [Google Scholar]
  23. Levitus G., Mertens F., Speranca M. A., Camargo L. M., Ferreira M. U., del Portillo H. A. Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax. Am J Trop Med Hyg. 1994 Jul;51(1):68–76. doi: 10.4269/ajtmh.1994.51.68. [DOI] [PubMed] [Google Scholar]
  24. Ling I. T., Ogun S. A., Holder A. A. Immunization against malaria with a recombinant protein. Parasite Immunol. 1994 Feb;16(2):63–67. doi: 10.1111/j.1365-3024.1994.tb00324.x. [DOI] [PubMed] [Google Scholar]
  25. Ling I. T., Ogun S. A., Holder A. A. The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite. Parasite Immunol. 1995 Aug;17(8):425–433. doi: 10.1111/j.1365-3024.1995.tb00910.x. [DOI] [PubMed] [Google Scholar]
  26. Mertens F., Levitus G., Camargo L. M., Ferreira M. U., Dutra A. P., Del Portillo H. A. Longitudinal study of naturally acquired humoral immune responses against the merozoite surface protein 1 of Plasmodium vivax in patients from Rondonia, Brazil. Am J Trop Med Hyg. 1993 Sep;49(3):383–392. doi: 10.4269/ajtmh.1993.49.383. [DOI] [PubMed] [Google Scholar]
  27. Müller H. M., Früh K., von Brunn A., Esposito F., Lombardi S., Crisanti A., Bujard H. Development of the human immune response against the major surface protein (gp190) of Plasmodium falciparum. Infect Immun. 1989 Dec;57(12):3765–3769. doi: 10.1128/iai.57.12.3765-3769.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nussenzweig R. S., Long C. A. Malaria vaccines: multiple targets. Science. 1994 Sep 2;265(5177):1381–1383. doi: 10.1126/science.8073276. [DOI] [PubMed] [Google Scholar]
  29. Pasay M. C., Cheng Q., Rzepczyk C., Saul A. Dimorphism of the C terminus of the Plasmodium vivax merozoite surface protein 1. Mol Biochem Parasitol. 1995 Mar;70(1-2):217–219. doi: 10.1016/0166-6851(95)00015-s. [DOI] [PubMed] [Google Scholar]
  30. Pirson P. J., Perkins M. E. Characterization with monoclonal antibodies of a surface antigen of Plasmodium falciparum merozoites. J Immunol. 1985 Mar;134(3):1946–1951. [PubMed] [Google Scholar]
  31. Porto M., Ferreira M. U., Camargo L. M., Premawansa S., del Portillo H. A. Second form in a segment of the merozoite surface protein 1 gene of Plasmodium vivax among isolates from Rondônia (Brazil). Mol Biochem Parasitol. 1992 Aug;54(1):121–124. doi: 10.1016/0166-6851(92)90104-r. [DOI] [PubMed] [Google Scholar]
  32. Premawansa S., Snewin V. A., Khouri E., Mendis K. N., David P. H. Plasmodium vivax:recombination between potential allelic types of the merozoite surface protein MSP1 in parasites isolated from patients. Exp Parasitol. 1993 Mar;76(2):192–199. doi: 10.1006/expr.1993.1022. [DOI] [PubMed] [Google Scholar]
  33. Riley E. M., Allen S. J., Wheeler J. G., Blackman M. J., Bennett S., Takacs B., Schönfeld H. J., Holder A. A., Greenwood B. M. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol. 1992 May;14(3):321–337. doi: 10.1111/j.1365-3024.1992.tb00471.x. [DOI] [PubMed] [Google Scholar]
  34. Shi Y. P., Sayed U., Qari S. H., Roberts J. M., Udhayakumar V., Oloo A. J., Hawley W. A., Kaslow D. C., Nahlen B. L., Lal A. A. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun. 1996 Jul;64(7):2716–2723. doi: 10.1128/iai.64.7.2716-2723.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Siddiqui W. A., Tam L. Q., Kramer K. J., Hui G. S., Case S. E., Yamaga K. M., Chang S. P., Chan E. B., Kan S. C. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci U S A. 1987 May;84(9):3014–3018. doi: 10.1073/pnas.84.9.3014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Taylor-Robinson A. W., Phillips R. S., Severn A., Moncada S., Liew F. Y. The role of TH1 and TH2 cells in a rodent malaria infection. Science. 1993 Jun 25;260(5116):1931–1934. doi: 10.1126/science.8100366. [DOI] [PubMed] [Google Scholar]
  37. Tolle R., Früh K., Doumbo O., Koita O., N'Diaye M., Fischer A., Dietz K., Bujard H. A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. Infect Immun. 1993 Jan;61(1):40–47. doi: 10.1128/iai.61.1.40-47.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Troye-Blomberg M., Riley E. M., Kabilan L., Holmberg M., Perlmann H., Andersson U., Heusser C. H., Perlmann P. Production by activated human T cells of interleukin 4 but not interferon-gamma is associated with elevated levels of serum antibodies to activating malaria antigens. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5484–5488. doi: 10.1073/pnas.87.14.5484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Udhayakumar V., Anyona D., Kariuki S., Shi Y. P., Bloland P. B., Branch O. H., Weiss W., Nahlen B. L., Kaslow D. C., Lal A. A. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol. 1995 Jun 1;154(11):6022–6030. [PubMed] [Google Scholar]
  40. Zevering Y., Khamboonruang C., Rungruengthanakit K., Tungviboonchai L., Ruengpipattanapan J., Bathurst I., Barr P., Good M. F. Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6118–6122. doi: 10.1073/pnas.91.13.6118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. al-Yaman F., Genton B., Kramer K. J., Chang S. P., Hui G. S., Baisor M., Alpers M. P. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg. 1996 May;54(5):443–448. doi: 10.4269/ajtmh.1996.54.443. [DOI] [PubMed] [Google Scholar]
  42. al-Yaman F., Genton B., Kramer K. J., Taraika J., Chang S. P., Hui G. S., Alpers M. P. Acquired antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea. Trans R Soc Trop Med Hyg. 1995 Sep-Oct;89(5):555–559. doi: 10.1016/0035-9203(95)90106-x. [DOI] [PubMed] [Google Scholar]
  43. del Portillo H. A., Levitus G., Camargo L. M., Ferreira M. U., Mertens F. Human IgG responses against the N-terminal region of the Merozoite Surface Protein 1 of Plasmodium vivax. Mem Inst Oswaldo Cruz. 1992;87 (Suppl 3):77–84. doi: 10.1590/s0074-02761992000700010. [DOI] [PubMed] [Google Scholar]
  44. del Portillo H. A., Longacre S., Khouri E., David P. H. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc Natl Acad Sci U S A. 1991 May 1;88(9):4030–4034. doi: 10.1073/pnas.88.9.4030. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES